Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,256Revenue (TTM) $M43.8Net Margin (%)-591.6Altman Z-Score-3.1
Enterprise Value $M1,136EPS (TTM) $-6.6Operating Margin %-572.1Piotroski F-Score2
P/E(ttm)--Beneish M-Score-5.4Pre-tax Margin (%)-593.2Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.2Cash flow > EarningsY
Price/Sales25.75-y EBITDA Growth Rate %--Current Ratio2.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-113.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-30,747.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M43.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CHRS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CHRSGeorge Soros 2016-03-31 Sold Out -0.05%$12.54 - $22.96
($16.44)
$ 28.9576%Sold Out0
CHRSGeorge Soros 2015-06-30 Buy 0.04%$21.07 - $30.58
($25.36)
$ 28.9514%New holding127,600
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CHRS is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CHRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FMR LLCSee Remark 1 2016-08-08Sell100,000$29.86-3.05view
Watler Peter K.Chief Technical Officer 2016-08-08Sell55,621$30-3.5view
FMR LLCSee Remark 1 2016-08-05Sell48,600$28.481.65view
Herman Alan C.Chief Scientific Officer 2016-08-01Sell11,333$25.5413.35view
Watler Peter K.Chief Technical Officer 2016-07-21Sell3,991$26.1310.79view
Watler Peter K.Chief Technical Officer 2016-07-20Sell73,741$25.0215.71view
Watler Peter K.Chief Technical Officer 2016-07-11Sell43,495$20.0244.61view
Herman Alan C.Chief Scientific Officer 2016-07-01Sell4,250$16.8971.4view
Herman Alan C.Chief Scientific Officer 2016-06-01Sell4,250$18.6755.06view
Watler Peter K.Chief Technical Officer 2016-05-17Sell12,000$2044.75view

Quarterly/Annual Reports about CHRS:

News about CHRS:

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
COHERUS BIOSCIENCES, INC. Financials Aug 18 2016
Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN) Aug 16 2016
ETF’s with exposure to Coherus BioSciences, Inc. : August 15, 2016 Aug 15 2016
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Yelp Inc (YELP) Swung To Surprising Profit; A Look at Four Other Earnings Reports Aug 10 2016
Coherus BioSciences reports 2Q loss Aug 09 2016
Coherus BioSciences reports 2Q loss Aug 09 2016
Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today Aug 09 2016
Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results Aug 09 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other... Aug 09 2016
Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results Aug 09 2016
Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug... Aug 09 2016
Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug... Aug 09 2016
Q2 2016 Coherus BioSciences Inc Earnings Release - After Market Close Aug 09 2016
Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar... Aug 08 2016
Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar... Aug 08 2016
Coverage initiated on Coherus BioSciences by Citigroup Jul 27 2016
Coherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th Jul 25 2016
Coherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th Jul 25 2016
These new drugs might never get a chance to save the U.S. $250 billion Jul 20 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)